▶ 調査レポート

GLP-1医薬品の世界市場見通し2023年-2029年

• 英文タイトル:GLP-1 Drug Market, Global Outlook and Forecast 2023-2029

Market Monitor Globalが調査・発行した産業分析レポートです。GLP-1医薬品の世界市場見通し2023年-2029年 / GLP-1 Drug Market, Global Outlook and Forecast 2023-2029 / MRC2312MG10279資料のイメージです。• レポートコード:MRC2312MG10279
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英文、PDF、77ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥455,000 (USD3,250)▷ お問い合わせ
  Enterprise User¥682,500 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
当調査レポートは次の情報を含め、世界のGLP-1医薬品市場規模と予測を収録しています。・世界のGLP-1医薬品市場:売上、2018年-2023年、2024年-2029年
・世界のGLP-1医薬品市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界のGLP-1医薬品市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「短時間作用型GLP-1医薬品」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

GLP-1医薬品のグローバル主要企業は、Eli Lilly、 AstraZeneca、 Sanofi、 Pfizer Inc、 Novo Nordisk、 Boehringer Ingelheim、 GlaxoSmithKline (GSK)、 East China Pharmaceutical Co., Ltd.、 Gan & Lee Pharmaceuticals、 Tonghua Dongbao、 Shanghai Renhui Biopharmaceutical Co., Ltd.、 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.などです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL(MMG)は、GLP-1医薬品のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界のGLP-1医薬品市場:タイプ別、2018年-2023年、2024年-2029年
世界のGLP-1医薬品市場:タイプ別市場シェア、2022年
・短時間作用型GLP-1医薬品、長時間作用型GLP-1医薬品

世界のGLP-1医薬品市場:用途別、2018年-2023年、2024年-2029年
世界のGLP-1医薬品市場:用途別市場シェア、2022年
・肥満、2型糖尿病、心血管&脳血管疾患、非アルコール性脂肪性肝炎、アルツハイマー病

世界のGLP-1医薬品市場:地域・国別、2018年-2023年、2024年-2029年
世界のGLP-1医薬品市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業におけるGLP-1医薬品のグローバル売上、2018年-2023年
・主要企業におけるGLP-1医薬品のグローバル売上シェア、2022年
・主要企業におけるGLP-1医薬品のグローバル販売量、2018年-2023年
・主要企業におけるGLP-1医薬品のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Eli Lilly、 AstraZeneca、 Sanofi、 Pfizer Inc、 Novo Nordisk、 Boehringer Ingelheim、 GlaxoSmithKline (GSK)、 East China Pharmaceutical Co., Ltd.、 Gan & Lee Pharmaceuticals、 Tonghua Dongbao、 Shanghai Renhui Biopharmaceutical Co., Ltd.、 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.

*************************************************************

・調査・分析レポートの概要
GLP-1医薬品市場の定義
市場セグメント
世界のGLP-1医薬品市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界のGLP-1医薬品市場規模
世界のGLP-1医薬品市場規模:2022年 VS 2029年
世界のGLP-1医薬品市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでのGLP-1医薬品の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業のGLP-1医薬品製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:短時間作用型GLP-1医薬品、長時間作用型GLP-1医薬品
GLP-1医薬品のタイプ別グローバル売上・予測

・用途別市場分析
用途区分:肥満、2型糖尿病、心血管&脳血管疾患、非アルコール性脂肪性肝炎、アルツハイマー病
GLP-1医薬品の用途別グローバル売上・予測

・地域別市場分析
地域別GLP-1医薬品市場規模 2022年と2029年
地域別GLP-1医薬品売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル(企業概要、事業概要、主要製品、売上、ニュースなど)
Eli Lilly、 AstraZeneca、 Sanofi、 Pfizer Inc、 Novo Nordisk、 Boehringer Ingelheim、 GlaxoSmithKline (GSK)、 East China Pharmaceutical Co., Ltd.、 Gan & Lee Pharmaceuticals、 Tonghua Dongbao、 Shanghai Renhui Biopharmaceutical Co., Ltd.、 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
...

This research report provides a comprehensive analysis of the GLP-1 Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global GLP-1 Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of GLP-1 Drug, challenges faced by the industry, and potential opportunities for market players.
The global GLP-1 Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The GLP-1 Drug market presents opportunities for various stakeholders, including Obesity, Type 2 Diabetes (T2DM). Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in GLP-1 Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global GLP-1 Drug market was valued at US$ 19270 million in 2022 and is projected to reach US$ 100560 million by 2029, at a CAGR of 27.1% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the GLP-1 Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the GLP-1 Drug market.
Market Overview: The report provides a comprehensive overview of the GLP-1 Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Short-acting GLP-1 Drug, Long-acting GLP-1 Drug), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the GLP-1 Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the GLP-1 Drug market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the GLP-1 Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the GLP-1 Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the GLP-1 Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the GLP-1 Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for GLP-1 Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the GLP-1 Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
GLP-1 Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Short-acting GLP-1 Drug
Long-acting GLP-1 Drug
Market segment by Application
Obesity
Type 2 Diabetes (T2DM)
Cardiovascular and Cerebrovascular Diseases (CVD)
Non-alcoholic Steatohepatitis (NASH)
Alzheimer’s Disease (AD)
Global GLP-1 Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Eli Lilly
AstraZeneca
Sanofi
Pfizer Inc
Novo Nordisk
Boehringer Ingelheim
GlaxoSmithKline (GSK)
East China Pharmaceutical Co., Ltd.
Gan & Lee Pharmaceuticals
Tonghua Dongbao
Shanghai Renhui Biopharmaceutical Co., Ltd.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
Outline of Major Chapters:
Chapter 1: Introduces the definition of GLP-1 Drug, market overview.
Chapter 2: Global GLP-1 Drug market size in revenue and volume.
Chapter 3: Detailed analysis of GLP-1 Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of GLP-1 Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global GLP-1 Drug capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 GLP-1 Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global GLP-1 Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global GLP-1 Drug Overall Market Size
2.1 Global GLP-1 Drug Market Size: 2022 VS 2029
2.2 Global GLP-1 Drug Revenue, Prospects & Forecasts: 2018-2029
2.3 Global GLP-1 Drug Sales: 2018-2029
3 Company Landscape
3.1 Top GLP-1 Drug Players in Global Market
3.2 Top Global GLP-1 Drug Companies Ranked by Revenue
3.3 Global GLP-1 Drug Revenue by Companies
3.4 Global GLP-1 Drug Sales by Companies
3.5 Global GLP-1 Drug Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 GLP-1 Drug Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers GLP-1 Drug Product Type
3.8 Tier 1, Tier 2 and Tier 3 GLP-1 Drug Players in Global Market
3.8.1 List of Global Tier 1 GLP-1 Drug Companies
3.8.2 List of Global Tier 2 and Tier 3 GLP-1 Drug Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global GLP-1 Drug Market Size Markets, 2022 & 2029
4.1.2 Short-acting GLP-1 Drug
4.1.3 Long-acting GLP-1 Drug
4.2 By Type – Global GLP-1 Drug Revenue & Forecasts
4.2.1 By Type – Global GLP-1 Drug Revenue, 2018-2023
4.2.2 By Type – Global GLP-1 Drug Revenue, 2024-2029
4.2.3 By Type – Global GLP-1 Drug Revenue Market Share, 2018-2029
4.3 By Type – Global GLP-1 Drug Sales & Forecasts
4.3.1 By Type – Global GLP-1 Drug Sales, 2018-2023
4.3.2 By Type – Global GLP-1 Drug Sales, 2024-2029
4.3.3 By Type – Global GLP-1 Drug Sales Market Share, 2018-2029
4.4 By Type – Global GLP-1 Drug Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global GLP-1 Drug Market Size, 2022 & 2029
5.1.2 Obesity
5.1.3 Type 2 Diabetes (T2DM)
5.1.4 Cardiovascular and Cerebrovascular Diseases (CVD)
5.1.5 Non-alcoholic Steatohepatitis (NASH)
5.1.6 Alzheimer’s Disease (AD)
5.2 By Application – Global GLP-1 Drug Revenue & Forecasts
5.2.1 By Application – Global GLP-1 Drug Revenue, 2018-2023
5.2.2 By Application – Global GLP-1 Drug Revenue, 2024-2029
5.2.3 By Application – Global GLP-1 Drug Revenue Market Share, 2018-2029
5.3 By Application – Global GLP-1 Drug Sales & Forecasts
5.3.1 By Application – Global GLP-1 Drug Sales, 2018-2023
5.3.2 By Application – Global GLP-1 Drug Sales, 2024-2029
5.3.3 By Application – Global GLP-1 Drug Sales Market Share, 2018-2029
5.4 By Application – Global GLP-1 Drug Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global GLP-1 Drug Market Size, 2022 & 2029
6.2 By Region – Global GLP-1 Drug Revenue & Forecasts
6.2.1 By Region – Global GLP-1 Drug Revenue, 2018-2023
6.2.2 By Region – Global GLP-1 Drug Revenue, 2024-2029
6.2.3 By Region – Global GLP-1 Drug Revenue Market Share, 2018-2029
6.3 By Region – Global GLP-1 Drug Sales & Forecasts
6.3.1 By Region – Global GLP-1 Drug Sales, 2018-2023
6.3.2 By Region – Global GLP-1 Drug Sales, 2024-2029
6.3.3 By Region – Global GLP-1 Drug Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America GLP-1 Drug Revenue, 2018-2029
6.4.2 By Country – North America GLP-1 Drug Sales, 2018-2029
6.4.3 US GLP-1 Drug Market Size, 2018-2029
6.4.4 Canada GLP-1 Drug Market Size, 2018-2029
6.4.5 Mexico GLP-1 Drug Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe GLP-1 Drug Revenue, 2018-2029
6.5.2 By Country – Europe GLP-1 Drug Sales, 2018-2029
6.5.3 Germany GLP-1 Drug Market Size, 2018-2029
6.5.4 France GLP-1 Drug Market Size, 2018-2029
6.5.5 U.K. GLP-1 Drug Market Size, 2018-2029
6.5.6 Italy GLP-1 Drug Market Size, 2018-2029
6.5.7 Russia GLP-1 Drug Market Size, 2018-2029
6.5.8 Nordic Countries GLP-1 Drug Market Size, 2018-2029
6.5.9 Benelux GLP-1 Drug Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia GLP-1 Drug Revenue, 2018-2029
6.6.2 By Region – Asia GLP-1 Drug Sales, 2018-2029
6.6.3 China GLP-1 Drug Market Size, 2018-2029
6.6.4 Japan GLP-1 Drug Market Size, 2018-2029
6.6.5 South Korea GLP-1 Drug Market Size, 2018-2029
6.6.6 Southeast Asia GLP-1 Drug Market Size, 2018-2029
6.6.7 India GLP-1 Drug Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America GLP-1 Drug Revenue, 2018-2029
6.7.2 By Country – South America GLP-1 Drug Sales, 2018-2029
6.7.3 Brazil GLP-1 Drug Market Size, 2018-2029
6.7.4 Argentina GLP-1 Drug Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa GLP-1 Drug Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa GLP-1 Drug Sales, 2018-2029
6.8.3 Turkey GLP-1 Drug Market Size, 2018-2029
6.8.4 Israel GLP-1 Drug Market Size, 2018-2029
6.8.5 Saudi Arabia GLP-1 Drug Market Size, 2018-2029
6.8.6 UAE GLP-1 Drug Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Eli Lilly
7.1.1 Eli Lilly Company Summary
7.1.2 Eli Lilly Business Overview
7.1.3 Eli Lilly GLP-1 Drug Major Product Offerings
7.1.4 Eli Lilly GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.1.5 Eli Lilly Key News & Latest Developments
7.2 AstraZeneca
7.2.1 AstraZeneca Company Summary
7.2.2 AstraZeneca Business Overview
7.2.3 AstraZeneca GLP-1 Drug Major Product Offerings
7.2.4 AstraZeneca GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.2.5 AstraZeneca Key News & Latest Developments
7.3 Sanofi
7.3.1 Sanofi Company Summary
7.3.2 Sanofi Business Overview
7.3.3 Sanofi GLP-1 Drug Major Product Offerings
7.3.4 Sanofi GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.3.5 Sanofi Key News & Latest Developments
7.4 Pfizer Inc
7.4.1 Pfizer Inc Company Summary
7.4.2 Pfizer Inc Business Overview
7.4.3 Pfizer Inc GLP-1 Drug Major Product Offerings
7.4.4 Pfizer Inc GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.4.5 Pfizer Inc Key News & Latest Developments
7.5 Novo Nordisk
7.5.1 Novo Nordisk Company Summary
7.5.2 Novo Nordisk Business Overview
7.5.3 Novo Nordisk GLP-1 Drug Major Product Offerings
7.5.4 Novo Nordisk GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.5.5 Novo Nordisk Key News & Latest Developments
7.6 Boehringer Ingelheim
7.6.1 Boehringer Ingelheim Company Summary
7.6.2 Boehringer Ingelheim Business Overview
7.6.3 Boehringer Ingelheim GLP-1 Drug Major Product Offerings
7.6.4 Boehringer Ingelheim GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.6.5 Boehringer Ingelheim Key News & Latest Developments
7.7 GlaxoSmithKline (GSK)
7.7.1 GlaxoSmithKline (GSK) Company Summary
7.7.2 GlaxoSmithKline (GSK) Business Overview
7.7.3 GlaxoSmithKline (GSK) GLP-1 Drug Major Product Offerings
7.7.4 GlaxoSmithKline (GSK) GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.7.5 GlaxoSmithKline (GSK) Key News & Latest Developments
7.8 East China Pharmaceutical Co., Ltd.
7.8.1 East China Pharmaceutical Co., Ltd. Company Summary
7.8.2 East China Pharmaceutical Co., Ltd. Business Overview
7.8.3 East China Pharmaceutical Co., Ltd. GLP-1 Drug Major Product Offerings
7.8.4 East China Pharmaceutical Co., Ltd. GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.8.5 East China Pharmaceutical Co., Ltd. Key News & Latest Developments
7.9 Gan & Lee Pharmaceuticals
7.9.1 Gan & Lee Pharmaceuticals Company Summary
7.9.2 Gan & Lee Pharmaceuticals Business Overview
7.9.3 Gan & Lee Pharmaceuticals GLP-1 Drug Major Product Offerings
7.9.4 Gan & Lee Pharmaceuticals GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.9.5 Gan & Lee Pharmaceuticals Key News & Latest Developments
7.10 Tonghua Dongbao
7.10.1 Tonghua Dongbao Company Summary
7.10.2 Tonghua Dongbao Business Overview
7.10.3 Tonghua Dongbao GLP-1 Drug Major Product Offerings
7.10.4 Tonghua Dongbao GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.10.5 Tonghua Dongbao Key News & Latest Developments
7.11 Shanghai Renhui Biopharmaceutical Co., Ltd.
7.11.1 Shanghai Renhui Biopharmaceutical Co., Ltd. Company Summary
7.11.2 Shanghai Renhui Biopharmaceutical Co., Ltd. Business Overview
7.11.3 Shanghai Renhui Biopharmaceutical Co., Ltd. GLP-1 Drug Major Product Offerings
7.11.4 Shanghai Renhui Biopharmaceutical Co., Ltd. GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.11.5 Shanghai Renhui Biopharmaceutical Co., Ltd. Key News & Latest Developments
7.12 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
7.12.1 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Company Summary
7.12.2 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Business Overview
7.12.3 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Major Product Offerings
7.12.4 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. GLP-1 Drug Sales and Revenue in Global (2018-2023)
7.12.5 Jiangsu Hansoh Pharmaceutical Group Co., Ltd. Key News & Latest Developments
8 Global GLP-1 Drug Production Capacity, Analysis
8.1 Global GLP-1 Drug Production Capacity, 2018-2029
8.2 GLP-1 Drug Production Capacity of Key Manufacturers in Global Market
8.3 Global GLP-1 Drug Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 GLP-1 Drug Supply Chain Analysis
10.1 GLP-1 Drug Industry Value Chain
10.2 GLP-1 Drug Upstream Market
10.3 GLP-1 Drug Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 GLP-1 Drug Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer